Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan, Capecitabine, and Enlonstobart + SCRT for Locally Advanced Rectal Cancer
NCT07281157Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Nov 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of PBI-1308 in rectal cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Nov 2025; status: recruiting.
02
Drugs
PBI-1308
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07281157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281157.